Patents by Inventor John W. Holaday
John W. Holaday has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10532385Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: GrantFiled: June 29, 2017Date of Patent: January 14, 2020Assignee: DisposeRx, Inc.Inventors: Marcus Schestopol, Donald Treacy, Edward M. Rudnic, Beth A. Burnside, John W. Holaday
-
Publication number: 20190358687Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: ApplicationFiled: August 9, 2019Publication date: November 28, 2019Inventors: Marcus Schestopol, Donald Treacy, Edward M. Rudnic, Beth A. Burnside, John W. Holaday
-
Publication number: 20190025314Abstract: The present invention relates to a method of determining the major histocompatibility complex profile of a tumour subject with cancer comprising the steps of: a) obtaining a physiological fluid sample comprising texosomes or a texosome-enriched sample of extracellular vesicles from a physiological fluid sample of the subject; and b) identifying the phenotype of texosomes associated with tumour cells having aberrant MHC-I expression to determine the major histocompatibility complex profile of the tumour of the subject; as well as various stratifications for immunotherapy, methods of prognosis of cancer in a subject and methods of treatment based on the MHC-I or HLA-G expression profile.Type: ApplicationFiled: January 11, 2017Publication date: January 24, 2019Inventors: Janette Dixon, John W. Holaday
-
Publication number: 20180333557Abstract: The present technology relates to a device and method to provide distilled water in pre-filled, disposable containers for use with humidifiers in assisted breathing units, such as continuous positive airway pressure (CPAP) devices. The technology also relates to methods for delivery of medications and inhalational and/or aromatic therapies through heated hydration chambers in CPAP devices and/or through nebulizers to be used to hydrate air in conjunction with CPAP devices. The present technology further relates to convenient multi-packs of pre-filled, disposable water containers to be provided in conjunction with CPAP devices.Type: ApplicationFiled: May 18, 2018Publication date: November 22, 2018Inventor: John W. HOLADAY
-
Publication number: 20180001357Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Applicant: DisposeRx, Inc.Inventors: MARCUS SCHESTOPOL, DONALD TREACY, EDWARD M. RUDNIC, BETH A. BURNSIDE, JOHN W. HOLADAY
-
Publication number: 20160331922Abstract: The present technology relates to a device and method to provide distilled water in pre-filled, disposable containers for use with humidifiers in assisted breathing units, such as continuous positive airway pressure (CPAP) devices. The technology also relates to methods for delivery of medications and inhalational and/or aromatic therapies through heated hydration chambers in CPAP devices and/or through nebulizers to be used to hydrate air in conjunction with CPAP devices. The present technology further relates to convenient multi-packs of pre-filled, disposable water containers to be provided in conjunction with CPAP devices.Type: ApplicationFiled: December 22, 2014Publication date: November 17, 2016Inventor: John W. HOLADAY
-
Patent number: 9107878Abstract: The present invention relates to compositions and methods for treating an animal with a tumor or other metabolic disorder. In particular, the presently disclosed subject matter relates to methods of electroporating exosomes shed by tumors and by other metabolic disorders into immune cells such as dendritic cells and T cells. Administration of the electroporated immune cells to an animal with a tumor results in an increased immune response to the tumor and treatment of the tumor.Type: GrantFiled: April 6, 2011Date of Patent: August 18, 2015Assignee: EXOCYTE THERAPEUTICS PTE, LTDInventor: John W. Holaday
-
Publication number: 20150165052Abstract: Disclosed are hybrid opioid compounds, mixed opioid salts, compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particularly, in one aspect the hybrid opioid compound includes at least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical compositions, as well as to methods of treating pain in humans using the hybrid compounds and mixed opioid salts.Type: ApplicationFiled: May 10, 2013Publication date: June 18, 2015Inventors: John W. Holaday, Philip Magistro
-
Patent number: 8933092Abstract: Methods and compositions for the alleviation of pain in a patient. The methods and compositions sequentially administer a therapeutically effective amount of first compound having opioid receptor agonist activity, followed by a therapeutic effective amount of a second or subsequent compound(s) having opioid receptor agonist activity, one or more non-opioid analgesic compounds or one or more hybrid opioid compounds, or mixtures thereof. The methods and compositions effectively alleviate pain with a lower incidence of opioid-induced side effects.Type: GrantFiled: May 31, 2012Date of Patent: January 13, 2015Assignee: Qrxpharma LimitedInventor: John W. Holaday
-
Publication number: 20140183070Abstract: A device for the neutralization and disposal of unused medicaments, such as drugs or medications. The device generally comprises a means of storing disposal device material, which can render medicaments unusable, and a means of exposing the disposal device material to the medicaments when they are no longer in use. The device may be a medicament container comprising a reservoir to store the disposal device material, and a means to expose the disposal device material to the medicaments. Alternatively, the device may be a medicament closure or lid for use with a medicament container, in which the closure comprises a reservoir for storing the disposal device material and a means to expose the disposal device material to the medicaments.Type: ApplicationFiled: August 2, 2013Publication date: July 3, 2014Applicant: QRxPharma Ltd.Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Donald Treacy, Marcus Schestopol, Kristin Benokraitis, Ed Browka, Jessie Delgado, David Foshee
-
Publication number: 20140187842Abstract: Device for the neutralization and disposal of unused human or animal pharmaceutical medicament. The device comprises a disposal device material that contains one or more disposal device agents. The disposal device material may also contain additional components to promote mixing, or neutralization of the active agent of the medicament. The disposal device material can be in the form of pellets, beads, beadlets, granules, or the like, and can be incorporated into a disposal device reservoir. The disposal device can be dispensed with a medicament, and the device can be used when the patient has finished using the medicament and there is material left over for disposal.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicant: QRxPharma Ltd.Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Marcus Schestopol, Donald Treacy, Michael Vachon, Sean Higgins, Gary W. Pace
-
Publication number: 20130202644Abstract: The present invention relates to compositions and methods for treating an animal with a tumor or other metabolic disorder. In particular, the presently disclosed subject matter relates to methods of electroporating exosomes shed by tumors and by other metabolic disorders into immune cells such as dendritic cells and T cells. Administration of the electroporated immune cells to an animal with a tumor results in an increased immune response to the tumor and treatment of the tumor.Type: ApplicationFiled: April 6, 2011Publication date: August 8, 2013Inventor: John W. Holaday
-
Patent number: 8461171Abstract: Disclosed are hybrid opioid compounds, mixed opioid salts, compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particularly, in one aspect the hybrid opioid compound includes at least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical compositions, as well as to methods of treating pain in humans using the hybrid compounds and mixed opioid salts.Type: GrantFiled: February 9, 2011Date of Patent: June 11, 2013Assignee: QRxPHARMA Ltd.Inventors: John W. Holaday, Philip Magistro
-
Publication number: 20120309779Abstract: Methods and compositions for the alleviation of pain in a patient. The methods and compositions sequentially administer a therapeutically effective amount of first compound having opioid receptor agonist activity, followed by a therapeutic effective amount of a second or subsequent compound(s) having opioid receptor agonist activity, one or more non-opioid analgesic compounds or one or more hybrid opioid compounds, or mixtures thereof. The methods and compositions effectively alleviate pain with a lower incidence of opioid-induced side effects.Type: ApplicationFiled: May 31, 2012Publication date: December 6, 2012Inventor: John W. HOLADAY
-
Publication number: 20110245287Abstract: Disclosed are hybrid opioid compounds, mixed opioid salts, compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particularly, in one aspect the hybrid opioid compound includes at least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical compositions, as well as to methods of treating pain in humans using the hybrid compounds and mixed opioid salts.Type: ApplicationFiled: February 9, 2011Publication date: October 6, 2011Inventors: John W. Holaday, Philip Magistro
-
Publication number: 20080138877Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: ApplicationFiled: March 6, 2007Publication date: June 12, 2008Inventors: Sergey M. Dzekunov, Hyung J. Lee, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday
-
Patent number: 7186559Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: January 5, 2004Date of Patent: March 6, 2007Assignee: Maxcyte, Inc.Inventors: Sergey M. Dzekunov, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday, Hyung J. Lee
-
Patent number: 7141425Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: August 21, 2002Date of Patent: November 28, 2006Assignee: Maxcyte, Inc.Inventors: Sergey M. Dzekunov, Hyung J. Lee, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday
-
Patent number: 7029916Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: February 21, 2002Date of Patent: April 18, 2006Assignee: MAXCYTE, Inc.Inventors: Sergey M. Dzekunov, Hyung J. Lee, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday
-
Publication number: 20040253226Abstract: Compositions and methods for regulating angiogenic activity wherein the compositions comprise serine proteases including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: ApplicationFiled: February 12, 2004Publication date: December 16, 2004Inventors: John W. Holaday, Anne H. Fortier